Chen Daishi, Xu Ming, Wu Beibei, Chen Lei
Department of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Chinese PLA Medical School, 100853 Beijing, China.
Department of Otorhinolaryngology, The Affiliated Hospital of Ningbo University Medical College, 315020 Ningbo, China.
J Otol. 2017 Jun;12(2):47-54. doi: 10.1016/j.joto.2017.04.002. Epub 2017 Apr 28.
Hearing loss is one of the most frequent health issues in industrialized countries. The pathogenesis and molecular mechanisms of hearing loss are still unclear. Histone deacetylases (HDACs) are emerging as key enzymes in many physiological processes, including chromatin remodeling, regulation of transcription, DNA repair, metabolism, genome stability and protein secretion. Recent studies indicated that HDACs are associated with the development and progression of hearing loss. Dysfunction of HDACs could promote the oxidative stress and aging in the inner ear. In light of considering the current stagnation in the development of therapeutic options, the need for new strategies in the treatment of hearing loss has never been so pressing. In this review, we will summarize the reported literatures for HDACs in hearing loss and discuss how HDAC family members show different performances for the possibility of process of diseases development. The possibility of pharmacological intervention on hearing loss opens a novel path in the treatment of hearing loss.
听力损失是工业化国家中最常见的健康问题之一。听力损失的发病机制和分子机制仍不清楚。组蛋白脱乙酰酶（HDACs）正在成为许多生理过程中的关键酶，包括染色质重塑、转录调控、DNA修复、代谢、基因组稳定性和蛋白质分泌。最近的研究表明，HDACs与听力损失的发生和发展有关。HDACs功能障碍可促进内耳的氧化应激和衰老。鉴于目前治疗方案开发的停滞不前，治疗听力损失的新策略的需求从未如此迫切。在这篇综述中，我们将总结已报道的关于HDACs在听力损失方面的文献，并讨论HDAC家族成员在疾病发展过程中的可能性方面如何表现出不同。对听力损失进行药物干预的可能性为听力损失的治疗开辟了一条新途径。
